Zevra Therapeutics (ZVRA) Liabilities and Shareholders Equity (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $278.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 61.3% year-over-year to $278.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 58.67% YoY) and the FY2025 annual result came in at $284.7 million, up 59.85% from the prior year.
• Liabilities and Shareholders Equity declined to $278.6 million in Q1 2026, from $284.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $284.7 million in Q4 2025 to a low of -$426000.0 in Q1 2022.
• A 5-year average of $168.9 million and a median of $161.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity tumbled 100.47% — and 2025, when it soared 77.47%.
• Tracing ZVRA's Liabilities and Shareholders Equity over 5 years: stood at $115.3 million in 2022, then surged by 49.41% to $172.3 million in 2023, then climbed by 3.37% to $178.1 million in 2024, then jumped by 59.85% to $284.7 million in 2025, then declined by 2.16% to $278.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $278.6 million (Q1 2026), $284.7 million (Q4 2025), and $270.1 million (Q3 2025), per Business Quant data.